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Abstract
Alzheimer’s disease (AD) is the most common neurodegenerative disorder causing huge emotional and economic
burden to our societies. An effective therapy has not been implicated yet, which is in part also due to the fact that
pathological changes occur years before clinical symptoms manifest. Thus, there is a great need for the development
of a translatable biomarker. Recent evidence highlights microRNAs as candidate biomarkers. In this study, we use next-
generation sequencing to study the small noncoding RNAome (sncRNAome) in exosomes derived from human
cerebrospinal fluid (CSF). We show that the sncRNAome from CSF-derived exosomes is dominated not only by
microRNAs (miRNAs) but also by PIWI-interacting RNAs (piRNAs). We define a combined signature consisting of three
miRNAs and three piRNAs that are suitable to detect AD with an AUC of 0.83 in a replication cohort and furthermore
predict the conversion of mild–cognitive impaired (MCI) patients to AD dementia with an AUC of 0.86 for the piRNA
signature. When combining the smallRNA signature with pTau and Aβ 42/40 ratio the AUC reaches 0.98. Our study
reports a novel exosomal small noncoding RNA signature to detect AD pathology and provides the first evidence that
in addition to miRNAs, piRNAs should also be considered as a candidate biomarker for AD.
Introduction
Alzheimer’s disease (AD) is the most common reason of
dementia in the elderly and is causing an increasing
social–economic burden to our societies. AD arises on the
pathological background of amyloid-beta deposition, the
formation of neurofibrillary tangles, neuroinflammation,
and neuronal cell death. Despite intensive research and an
increasing understanding of the molecular processes that
underlie AD1–4, an effective treatment has not been
implemented so far, which is also due to the fact that
suitable biomarkers that would allow the detection of
pathology in the preclinical stage are still missing. This is
of particular importance since pathological alterations
occur years before the presentation of clinical symptoms5.
Preclinical and prodromal disease stages are also the most
promising time points for intervention trials. As such,
there is great interest in molecular biomarkers that would
help to identify patients early, predict the course of dis-
ease, and indicate therapeutic efficacy in clinical trials6. A
recent line of research suggests that the analysis of cir-
culating small noncoding RNAs (sncRNA) could serve as
a diagnostic biomarker for various diseases7, including
AD dementia8. A major focus has been on the analysis of
microRNAs (miRNAs) that are 19–22-nucleotide-long
RNA molecules regulating protein homeostasis via bind-
ing to a target mRNA thereby causing its degradation or
inhibition of translation9. Recently, miRNAs have been
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implicated with learning and memory function10–13, and
the pathogenesis of neurodegenerative diseases including
AD14–19. For example, expression of specific miRNAs was
altered in the brains of AD dementia patients and in AD
animal models11,14,16,17,20, and preclinical data indicate
that targeting miRNAs could help to reinstate protein
homeostasis and memory function in AD11. Thus, miR-
NAs may offer an additional opportunity for patient
stratification and therapy. Such approaches have been very
promising in the field of oncology, and first-miRNA-based
therapies are now in clinical testing. A number of studies
have also investigated circulating microRNA expression in
AD dementia, including the analysis of cerebrospinal fluids
(CSF) by using PCR-based arrays, microarray, or more
recently also next-generation sequencing approaches20–24.
So far findings across studies are not consistent. Moreover,
the source of small noncoding RNAs in CSF is not entirely
clear. It has recently been shown that CSF miRNAs can be
detected in exosomes25–27. Exosomes are cell-derived
vesicles of 40–140-nm diameter that contribute to inter-
cellular signaling and disposal of superfluous cellular
content28,29. Exosomes have among other functions been
implicated in neuronal plasticity.
Here, we use next-generation sequencing to quantify the
smallRNA content in CSF exosomes in two independent
cohorts of AD dementia patients and age-matched con-
trols (Signature and replication cohort), and one pro-
spective cohort of patients with mild–cognitive
impairment (MCI) (DCN cohort). In contrast to miRNAs,
other small noncoding RNA species have been rarely
analyzed as candidate CSF biomarkers. The major sncRNA
species detected were miRNAs and piwi-interacting RNAs
(piRNA). We were able to identify a sncRNA signature
consisting of three miRNAs and three piRNAs that dis-
tinguishes AD dementia patients from individuals without
AD dementia with an AUC of 0.83. Importantly, sncRNAs
were also able to predict the conversion of mild–cognitive
impairment (MCI) patients to AD dementia with an AUC
of 0.86. When combining the smallRNA data with CSF
levels of Aβ 42, Tau, and pTau, we can detect AD patients
and predict the conversion from MCI to AD dementia
with AUC values of 0.98 and 0.97, respectively. We fur-
thermore show that our signature can distinguish AD
patients and non-demented control individuals when
postmortem brain samples are analyzed. In conclusion,
these data suggest that the analysis of exosomal smallR-
NAs, and especially piRNAs, could help to identify indi-
viduals at risk of developing AD dementia and improve the
stratification of individuals to clinical trials.
Methods
Western blotting
Western blotting was performed according to standard
protocols. Primary antibodies: mouse monoclonal
antibodies against Flotillin-2 (BD Biosciences), Alix (BD
Biosciences), TSG101 (GeneTex Inc., Irvine, CA, USA),
CD-63 (BD Biosciences), and rabbit anti-Calnexin
(StressGene). Secondary antibodies were obtained from
Dianova and Invitrogen.
Nanoparticle-tracking analysis
Exosomes in the ultracentrifugation pellet were ana-
lyzed by nanoparticle-tracking analysis with a NanoSight
LM10 instrument and a LM14 viewing unit equipped with
a 532-nm laser (NanoSight Ltd). Pellets from 100,000 × g
centrifugation derived from 0.5 ml of total CSF were
resuspended in 50 µl of PBS and diluted 1:40 in PBS.
Samples were recorded in triplicates for 30 s. Particle
numbers were then analyzed with the Nanoparticle
Tracking Analysis (NTA) 2.3 software.
Primary neuronal cell culture
Primary cortical and hippocampal neurons were pre-
pared from E16 NMRI mouse embryos and cultured on
poly-lysine-coated plastic dishes in serum-free MEM
supplemented with B27 (Invitrogen) as described pre-
viously30. For exosome preparations, cells were cultured
until day in vitro (DIV) 14. For exosome collection, cells
were washed three times in phosphate-buffered saline
(PBS) and incubated in fresh MEM B27 for 16 h. Culture
medium was then collected and subjected to subsequent
centrifugation steps performed at 4 °C: 3500 × g 10 min, 2
times 4500 × g for 10 min, 10,000 × g for 30 min, and
100,000 × g for 60 min. The 100,000 × g pellet was washed
once with PBS before resuspension in sample buffer or
Trizol. Parent cells were scraped into Trizol.
Cerebrospinal fluid collection
Human CSF samples (42 with Alzheimer’s dementia, 82
psychiatric and neurological controls, and 17 with MCI)
were collected from the Department of Psychiatry at
University Medical Center Göttingen (Germany), Uni-
versity Department of Neurology at University Hospital
Tübingen (Germany), and Paracelsus Elena clinic Kassel
(Germany) in two iterations between January
2012–March 2013 and April 2013–October 2014 with the
approval of IRB at University Medical Center Göttingen
(IRB 02/05/09), IRB approval by the local board of Hes-
sen, Germany, IRB 09/07/04 and 26/07/02, at Paracelsus
clinic Kassel and IRB approval 20/099/2011B01 for bio-
banking) at the Department of Neurology, Tübingen
(Germany). After obtaining informed consent, ~10ml of
cerebrospinal fluid (CSF) were collected by lumbar
puncture between 9 and 12 am. Thirty-eight randomly
selected samples obtained from the neurological controls
were used to confirm the presence of smallRNAs in CSF
exosomes as described in Fig. 1. Specimens were collected
in polypropylene tubes and centrifuged at 2000 × g for
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10min at room temperature (Göttingen and Kassel
cohorts) or 4 °C (Tübingen cohort), aliquoted, and frozen
at −80 °C within 30 min of completion of the procedure.
All samples were obtained in accordance with the ethical
standards laid down in the 1964 Declaration of Helsinki.
All AD dementia patients fulfilled the National Institute
of Neurological and Communicative Disorders and Stroke
and the Alzheimer’s Disease and Related Disorders
Association (NINCDS-ADRDA) and National Institute on
Aging and Alzheimer’s Association (NIAA) diagnosis
criteria for probable AD dementia31,32. We employed CSF
Aβ42 and CSF total Tau levels as fluid biomarkers in
patients upon neuropsychological testing (AD was clas-
sified as Aβ42 < 450 [pg/ml] and total Tau > 200 [pg/ml]).
Thus, AD pathology diagnosis was based on positive CSF
Aβ42 and total Tau levels, whereas all controls were
negative for these markers. Control CSFs included CSF
from cognitively healthy patients with depression,
cephalgy, schizophrenia, bipolar disorder, and poly-
neuropathy or were obtained from a cohort of healthy
controls that had undergone neuropsychological testing
to rule out cognitive impairment. None of the control
patients suffered from neurodegenerative disorders or
dementia. Based on these markers, we also defined two
groups of MCI patients in the DCI cohort (see below):
MCI due to AD and MCI control33,34. Only CSF samples
with normal routine parameters were used. Samples
with erythrocyte counts > 50/mm3 were excluded. CSF
Fig. 1 Analysis of the exosomal sncRNAome. a Exosomes isolated from human CSF were analyzed via EM (upper left panel), for fragment size by
using a nanosight instrument (right panel) and via immunoblot for exosomal marker proteins (lower panel). b Electropherogram showing the profile
of RNA isolated from exosomes. c Electropherogram showing the profile of RNA isolated from exosome-free CSF. d Electropherogram showing the
profile of RNA isolated from lysed exosomes treated with DNAase (left) and RNAase (right). e Left panel: Pie chart showing the distribution of small
noncoding RNAs in human CSF exosomes. Pie chart on the top right shows the genomic distribution of the human piRNAome for comparison. The
lower right pie chart shows genomic annotation of the human CSF exosomal piRNAome. Note that in contrast to the entire piRNAome (upper right
pie chart), the majority of piRNAs reside in the first exon of coding genes. f Top 5 expressed miRNAs (blue) and piRNAs (red) in human CSF exosomes.
g Heatmap showing expression values of the 3-p and 5-p arms of all miRNAs detected in human CSF and in the human cortex (Brodmann Area 9).
h Graphs showing Pearson correlation between miRNA (two left panels) and piRNA (two right panels) expression values of hippocampal and cortical
neurons vs. the corresponding miRNA and piRNA expression in exosomes released from these cells
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Aβ1-40/42, Tau, and phospho-tau (pTau) were deter-
mined with commercially available ELISA kits according
to the manufacturer’s protocol (Innogenetics NV, Ghent,
Belgium).
The longitudinal DCN cohort (dementia competence
network, DCN) of MCI patients
The Dementia Competence Network (DCN) cohort is a
prospective multicenter observational study on memory
clinic patients with MCI or early dementia. The DCN
study was approved by the Ethics Review Board of the
Erlangen medical faculty (coordinating center) and by the
Ethics Committees at each individual center, and was
conducted in accordance with the Declaration of Helsinki.
The 10-year follow-up study was approved by the Ethics
Committee of Göttingen University Medical center (IRB
40/7/02). All patients gave written informed consent to
participate. Participants were recruited between 2003 and
2007 at 13 specialist memory clinics in Germany. For
inclusion and exclusion criteria and a description of the
cohort please refer to ref. 35. A MCI diagnosis was made
on the basis of clinical and neuropsychological data, i.e.,
decline of cognitive abilities (>1 SD below age- and
education-adjusted norms) in at least one of the domains
of the Consortium to Establish a Registry of Dementia
(CERAD) neuropsychological test battery and no changes
in activities of daily living. We selected patients fulfilling
MCI criteria at baseline and from which CSF was available
and retrieved 10-year follow-up information either by
telephone interview or a site visit of patient and caregiver
to assess activities of daily living and cognitive functions.
All participants on whom we could obtain 10-year out-
come information, were included in our analysis (n= 17).
Human brain tissue
Postmortem tissue from the prefrontal cortex (Brod-
mann area 9) from individuals that did not suffer from
neurodegenerative diseases was obtained with ethical
approval from the Alzheimer’s disease Research Center
Brain bank at Massachusetts General Hospital, Boston,
MA and from Brigham & Women’s Hospital Autopsy
Service, Boston, MA, USA. Samples were matched for age
and postmortem delay (n= 9, male 7, female= 2; age=
60 ± 19 years; PMD 16 ± 4 h).
Neuropsychological procedures
All subjects were investigated with standardized neu-
ropsychological tests as described previously35. The
CERAD neuropsychological test battery includes verbal
and visuspatial learning subtests with immediate and
delayed recall, a naming test, a verbal fluency test, and the
Mini Mental State Examination test (MMSE). We here
focused on the verbal-delayed free-recall (CERAD-DR)
measure. As a composite measure of overall dementia
severity, the CDR sum-of-boxes (CDR-sb) was addition-
ally applied in participants of the DNC cohort36. For
comparison with other cohorts, the MMSE was applied37.
Purification of exosomes from cerebrospinal fluid
Exosomes were isolated as described previously38–40
from 1ml starting volume. CSF was thawn on ice and
subjected to subsequent centrifugation steps at 4 °C:
3,500 × g for 10 min, two times 4,500 × g for 10 min,
10,000 × g for 30 min, and 100,000 × g for 60 min. The
100,000 × g pellet containing the exosomes was washed
once with phosphate-buffered saline (PBS) at 100,000 × g
for 60 min before resuspension in 200 µl of TRI Reagent®
and stored at −80 °C for further use.
Electron microscopy
Exosomes were prepared from CSF as described above.
The 100,000 × g pellet was fixed with 4% paraformaldehyde
and adsorbed to glow-discharged Formvar-carbon-coated
copper grids by floating the grid for 10min on 5-µl droplets
on Parafilm. The grids were negatively stained with 2%
uranyl acetate containing 0.7M oxalate, pH 7.0, and imaged
with a LEO EM912 Omega electron microscope (Zeiss,
Oberkochen). Digital micrographs were obtained with an
on-axis 2048 _ 2048 CCD camera (Proscan, Scheuring).
RNA extraction and smallRNA sequencing
Fractions were stored at −80 °C until homogenization
with 1 ml of TRI Reagent®, treated with 25 µl/ml of DEPC.
After mixing with the 2 µl of glycogen, the mixture was
kept at room temperature for 5 min. Two-hundred
microliters of phenol–chloroform was added to the mix
and kept at room temperature for further 5 min after
vigorous shaking. After centrifugation for 15 min at
1200 × g, the aqueous phase containing RNA, was col-
lected and incubated overnight in 500 µl of isopropanol at
−20 °C. The precipitated RNA was subsequently isolated
by 30min of centrifugation at 12,000 × g at 4 °C. The RNA
pellet was collected and washed two times with 75%
ethanol. The RNA pellet was air dried and suspended in
10 µl of water. Smallrna libraries were prepared by using
Illumina’s TruSeq® smallRNA kit following the manu-
facturer’s protocol.
SmallRNAseq reads preprocessing
For processing of sequencing data, a customized in-
house software pipeline was used. Illumina’s bcl2fastq (v
1.8.4) (Illumina, 2017) with default parameters was used
to convert the base calls in the per-cycle BCL files to the
per-read FASTQ format from raw images. Along with
base calling, adapter trimming, removal of Unique
Molecular Identifiers (UMIs), and demultiplexing were
performed. Quality control of raw sequencing data was
performed by using FastQC (v 0.11.5).
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Reads alignment and normalization
We first filtered out all the samples with library size
(total uniquely mapped reads) <50,000 reads. We calcu-
lated miRNAs and piRNAs normalized counts by using
Variance stabilization normalization (VSN)41–43. The
resulting VSN counts were corrected for various cohorts
along with the removal of the unwanted variances by
using the R (v 3.2.2)44 package RUVSeq (v 1.14.0)45. We
filtered out miRNAs and piRNAs that had a VSN read
count less than 0.5 in the 95% of control and diseased
samples, respectively. Thus, we obtained a set of 154
miRNAs and 43 piRNAs that were expressed and used for
downstream analysis.
Statistical and machine-learning analysis
In order to obtain a set of highly discriminative
smallRNAs, i.e., smallRNAs that separate one cohort from
another (e.g., controls from AD dementia), we used an
iterative feature-selection approach based on the appli-
cation of statistical and machine- learning techniques. In
specific, the procedure consisted of three iterations that
progressively trimmed down the initial set of sequenced
smallRNAs up to the point of leaving a manageable sig-
nature for random forest classification. In iteration 1, we
identified an initial subset of discriminatory smallRNAs by
applying the Measure of Relevance (MoR) method45 in
combination with reliability analysis (RiA), as described in
ref. 22. The MoR method ranks the discrimination power
of each smallRNA in an independent way, therefore
yielding a reduced list of candidate smallRNAs. RiA is
then subsequently applied as a control procedure to
validate the results of MoR. As a result of applying
Iteration 1, a reduced subset of smallRNAs was obtained.
In iteration 2, the smallRNAs derived from iteration 1
were filtered out by using a machine-learning variable
ranking method that is based on information-theoretic
principles46,47. In iteration 3, we filtered out all miRNAs
and piRNAs whose discriminative power was confounded
by age and gender by applying the multivariate analysis of
covariance (MANCOVA) analysis (Bonferroni corrected
significance with α= 0.05) (Table S1).
The performance of the selected features was then
evaluated on an independent test cohort. We used the
random forest algorithm implemented in R (v 3.2.2) with
the package randomforest (v 4.6.14). Input parameters
like average error and the average number of trees were
calculated by using a tenfold cross-validation on the
training data. Then by using the optimized input para-
meters, a model is trained with stratified sampling and
class weights (0.5, 1.0) for the control and the AD
dementia class to minimize the false negatives. The pre-
diction is performed on the replication cohort, and an
AUROC (area under the receiver-operating character-
istics) curve was used to estimate the performance from
the untouched replication cohort data. The AUC values
(with smoothing) were plotted by using the pROC pack-
age with 500 stratified bootstrap iterations along with the
confidence interval for the AUC values.
Results
CSF exosomes contain sncRNAs linked to brain function
We started our analysis with the aim to confirm pre-
vious findings suggesting that small noncoding RNAs
were present within CSF exosomes. To this end, we
obtained CSF from 38 individuals that did not suffer from
neurodegenerative diseases. Proper isolation of exosomes
was confirmed via immunoblot analysis for the marker
proteins Flotilin-2 and CD-63, electron microscopy, and
via the analysis of particle size (Fig. 1a). Next, we analyzed
RNA isolated from these exosomes and from the corre-
sponding exosomal-free CSF fraction via a bioanalyzer
microfluidic device. The corresponding electro-
pherograms show that a significant amount of RNA with a
particularly high peak indicating smallRNA species is
detectable in the exosomal CSF fraction (Fig. 1b). In
contrast, comparatively little RNA was obtained from the
corresponding exosome-free CSF (Fig. 1c). Treating RNA
samples obtained from CSF exosomes with DNAase did
not affect RNA integrity (Fig. 1d), while treatment with
RNAase eliminated the smallRNA peak (Fig. 1d). These
data provide further evidence that human CSF contains
exosomes that carry smallRNAs. Next we analyzed the
RNA content of CSF exosomes via smallRNA sequencing.
The smallRNA content was dominated by miRNAs and
piRNAs (Fig. 1e). The five highest-expressed miRNAs in
CSF exosomes were miR-10a-5p, miR-100-5p, miR-22-3p,
mIR-204-5p, and miR-26a (Fig. 1f) that have been pre-
viously linked to memory function and/or neurological
diseases27,48,49 (Fig. 1f). The five top-expressed piRNAs
showed comparable expression levels to miRNAs (Fig. 1f).
In contrast to miRNA, the role of piRNA is not well
established, but there is evidence that in addition to a role
in silencing repetitive genomic regions thereby mediating
genomic stability, some piRNAs are believed to play an
active role in gene-expression control50. It is thus inter-
esting that the piRNAs detected in the CSF exosomes are
mainly expressed from the first exon of a host gene
(Fig. 1e), a pattern that differs dramatically when com-
pared with all piRNAs encoded in the human genome that
are mainly expressed from intergenic regions (Fig. 1e).
Regarding the microRNAome, the 5- and the 3-p arm of a
given miRNA are often expressed at different levels. Since
for many microRNAs, the precise biological function is
still unclear, a suitable estimate to define if the 5-p or the
3-p arm of a given miRNA is biologically active, is to
quantify the expression of both arms and consider the
highest expressed arm to be the active one. It was pre-
viously suggested that the inactive arm of a given
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microRNA would be sorted into exosomes as a cellular-
clearance mechanism. At the same time, there is evidence
that exosomal transport of molecules from one cell to
another via exosomes serves important biological func-
tions51. To evaluate these possibilities in the context of
exosomal miRNAs from CSF, we performed smallRNA
sequencing from postmortem human prefrontal cortex
(Brodmann area 9, individuals without neurological dis-
ease) and compared the expression pattern of the 5-p and
3-p arms for all miRNAs detected in CSF exosomes with
the corresponding expression pattern observed in human
brain. The pattern of the 3-p vs. 5-p arms of microRNAs
detected in CSF was similar to the pattern observed in
postmortem human brain tissue and confirmed that for the
majority of the miRNAs only one arm was highly expressed
(Fig. 1g). This finding supports the view that the miRNA
content of CSF exosomes—at least in part—resembles the
miRNA content of the parental cell. These data have to be
interpreted with care, however, since the parental cell for
CSF exosomes is not precisely known and likely includes
various brain regions and also non-neural cells25. To fur-
ther address the question if the miRNA and piRNA content
of exosomes released from neurons would allow to make
conclusions about the corresponding cellular sncRNAome,
we decided to test the correlation of miRNA and piRNA
expression in primary cortical and hippocampal neurons
and in their corresponding exosomes. Exosomes were iso-
lated from the media supernatant of donor cells. Subse-
quently, the exosomal and the cellular RNA were prepared
and subjected to smallRNA sequencing. For both, miRNAs
and piRNAs, we detected a highly significant correlation
between cellular and exosomal fractions (Fig. 1h).
These data suggest that exosomes released from neu-
rons mainly represent the sncRNA composition of the
parental cells, a finding that is in line with other studies
performed, for example, on tumor cells52–54. It is there-
fore possible that the sncRNAome of CSF exosomes—at
least in part—reflects the scnRNAome of neuronal and
non-neuronal cells of the adult brain.
A CSF small noncoding RNA signature to diagnose AD
dementia patients
Next, we investigated the miRNA and piRNA expres-
sion from CSF exosomes in two independent cohorts of
AD dementia patients and controls. Cohort 1 (signature
identification cohort) consisted of 23 AD dementia
patients and 38 control individuals that did not suffer
from any neurodegenerative disorder (Fig. 2a). Samples
were collected at the University Medical Center Göttingen
(Germany), Department of Psychiatry, Göttingen (Ger-
many), and Department of Neurology at University
Tübingen (Germany) between January 2012 and March
2013. The replication cohort (Cohort 2, signature-testing
cohort) consisted of 19 AD dementia cases and 44 control
individuals from which CSF samples were collected at
University Medical Center Göttingen (Germany), Depart-
ment of Psychiatry, Göttingen (Germany), Department of
Neurology at University Tübingen (Germany), and Para-
celsus Elena clinic Kassel (Germany) between April 2013
and October 2014 (Fig. 2a). We decided to employ cohort
1 for the identification of a smallRNA signature suitable to
diagnose AD, while cohort 2 was used to test the per-
formance of such a signature in an independent replica-
tion cohort (Fig. 2a). We employed an iterative approach
to obtain an informative set of expressed and relevant
features (miRNAs and piRNAs) by using MoR55, relia-
bility analysis (RiA)22, machine-learning variable rank-
ing46,47, and multivariate analysis of covariances on cohort
1 to generate a model that would be able to classify AD
dementia patients and control individuals. We detected 3
miRNAs (Fig. 2b) and 3 piRNAs (Fig. 2c) as the most
relevant features that were not confounded by age and
gender (see also supplementary table 1). The identified
miRNAs were miR-27a-3p, miR-30a-5p, and miR-34c
(Fig. 2b) that have all been linked to memory function and
neurodegeneration in previous studies11,21,56,57. The three
miRNAs were increased in AD dementia patients
(Fig. 2b). Regarding the piRNAs, piR_019324 was
decreased, while piR_019949 and piR_020364 were
increased in the analyzed CSF samples of AD dementia
patients (Fig. 2c). While AD dementia patients used in
this study were additionally diagnosed on the basis of CSF
Aβ42 and CSF total Tau levels as fluid biomarkers in
patients upon neuropsychological testing, for all partici-
pants of Cohort 1 and 2 measures for the CSF biomarker
pTau and Aβ40 were also available. Thus, we used pTau
and the Aβ42/40 ratio to train a model on cohort 1 that
was then tested on cohort 2 by using a tenfold CV random
forest algorithm. As expected, the combination of pTau
levels and the Aβ42/40 ratio were able to classify AD
dementia patients with high sensitivity and specificity
(Fig. 2d). Of note, almost none of the identified miRNAs
and piRNAs were significantly correlated to pTau or
Aβ42/40 ratio levels, indicating that these smallRNAs do
not simply reflect changes in pTau or amyloid pathology
(Fig. 2e). The performance of our sncRNA model was
then tested on the replication cohort by using a tenfold
CV random forest algorithm. The miRNA/piRNA sig-
nature was able to distinguish AD dementia patients from
controls with an AUC of 0.83 that was similar to that of
pTau and Aβ42/40 ratio (Fig. 2f). Since our data indicated
that the information encoded in the miRNA/piRNA sig-
nature does not simply reflect changes in Tau and amy-
loid pathology, we decided to combine the measures of
pTau and Aβ42/40 ratio and our miRNA/piRNA sig-
nature. By this approach, we were able to classify AD
dementia patients in the replication cohort correctly in
98% of the cases (Fig. 2g).
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A piRNA signature to predict conversion from MCI to AD
dementia
Our data suggest that the analysis of miRNAs and
piRNAs in CSF exosomes can improve the antemortem
diagnosis of AD and might therefore also help to stratify
patients for clinical trials. From a therapeutic point of
view, it is of importance to develop a biomarker that could
also help to predict the conversion of patients suffering
from mild–cognitive impairment (MCI) to AD dementia.
To address this question, we obtained CSF exosomes
from individuals that were diagnosed with MCI and
subjected to CSF collection between 2003 and 2004 (DCN
cohort). Ten years later, 6 individuals had progressed to
AD dementia, while 11 patients had developed stable MCI
(Fig. 3a). Next, we tested if our miRNA/piRNA signature
(see Fig. 2) would be able to also distinguish stable MCI
patients from those that would convert to AD dementia in
the DCN cohort. While the combined miRNA/piRNA
signature had only limited predictive value, we noticed
that this was due to the miRNAs (Fig. S1). Interestingly,
we observed that the piRNA signature could predict
conversion from MCI to AD with an AUC of 0.86
(Fig. 3b). Notably, when we combined the analysis of the
piRNA signature with measures of pTau and the Aβ42/40
ratio, we were able to predict conversion from MCI to AD
dementia with an AUC of 0.96 (Fig. 3c). In contrast,
combined measures of pTau and the Aβ42/40 ratio pre-
dicted the progression to AD dementia with a compara-
tively lower AUC of 0.59 (Fig. S1C).
A miRNA/piRNA signature is able to classify AD dementia
patients on the basis of postmortem brain tissue
The finding that our miRNA/piRNA signature helps to
diagnose AD and may also help predict conversion of
Fig. 2 A sncRNA signature to diagnose AD patients. a Demographic information of the human cohorts used for signature identification and
testing. b Measure of Relevance (MoR) analysis for miRNA differences between AD and control samples in the signature cohort. The dotted red line
represents the critical MoR value cut off. miRNAs above the dotted red line are considered informative. miRNAs marked in blue are not confounded
by age and gender after MANCOVA analysis. The inset shows fold-change (log2) value of the three identified miRNAs between control and AD
patients. Their significance level (Bonferroni-corrected p value <= 0.05) with their significance codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘’ 1 is shown on
the top of the bars. c Measure of Relevance (MoR) analysis for piRNA differences between AD and control samples in the signature cohort. The dotted
red line represents the critical MoR value cutoff. piRNAs above the dotted red line are considered informative. piRNAs marked in red are not
confounded by age and gender after MANCOVA analysis. The inset shows the fold-change (log2) value of the three identified piRNAs between
control and AD patients. Their significance level (Bonferroni-corrected p value ≤0.05) with their significance codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’
1 is shown on the top of the bars. d Receiver-operating characteristic (ROC) plot was obtained during the performance testing by using pTau levels
and Aβ42/40 ratio obtained from CSF samples of the signature cohort on the replication cohort. Training was performed on the signature cohort
with a tenfold cross-validation. The inset plot shows the variable importance. e Heatmap showing Pearson correlation coefficient between
normalized expression of the sncRNA signature, pTau, and Aβ42/40 ratio in the signature cohort. Note that the sncRNA signature does not correlate
significantly with pTau levels and Aβ42/40 ratio. f ROC showing performance of the six sncRNA signatures when tested on the replication cohort.
Training was done on the signature cohort with a tenfold cross-validation. The inset plot shows the variable importance of the six individual sncRNAs.
g ROC showing performance of the combined 6 sncRNA signatures with pTau and Aβ42/40 ratio levels on the replication. A mean AUC of 0.98 was
obtained. F, female; M, male
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MCI to AD dementia in independent replication cohorts
is particularly interesting. To gain first insight, if the
identified miRNA/piRNA signature may also inform
about the relevant pathomechanisms in the brain, we
decided to employ a published dataset in which smallR-
NAome analysis had been performed on postmortem
human brain tissue (prefrontal cortex) from AD dementia
patients and age-matched controls (Fig. 4a; P= 0.7 for age
between AD and control, ANOVA)58. We then asked if
our miRNA/piRNA signature would be able to classify AD
dementia patients and controls on the basis of the
sequencing dataset available from these postmortem
human brains. Our analysis revealed that our signature
was able to classify AD dementia patients and controls
with an AUC of 0.89 (Fig. 4b). This finding indicates that
the CSF exosomal miRNA/piRNA signature might inform
—at least in part—about the pathomechanisms in the
brain. We therefore also performed a pathway analysis of
the confirmed target genes on the three microRNAs.
When we analyzed the pathways linked to the confirmed
target genes of all three microRNAs, we identified path-
ways highly relevant to AD, namely pathways linked to
inflammatory processes, to IGF1 and mTOR signaling,
and to HIF1alpha-related hypoxia59–62 (Fig. 4c). A num-
ber of genes were targeted by all three identified micro-
RNAs and we named these genes “hub genes” (Fig. 4c).
When we analyzed the predicted targets of these “hub
genes” the most pronounced pathway was related to
HIF1alpha-mediated hypoxia, followed by pathways
linked to inflammatory processes and regulation of
androgen receptor activity that has also been recently
linked to AD63 (Fig. 4c).
In contrast to miRNAs, the role of piRNA is less well
established. While the majority of piRNAs in the human
genome are expressed from intergenic regions (see Fig. 1),
the CSF-expressed piRNAs, including the three piRNAs of
our signature, are mainly expressed from the first exon of
coding genes. The corresponding genes are listed in
Supplementary Table 2 (Table S2) and include genes
linked to Alzheimer’s disease such as phospholipase A264.
In conclusion, these data further support the view that the
identified miRNA/piRNA signature might reflect changes
in pathways highly relevant to AD pathogenesis.
Discussion
Several studies suggest that the analysis of the miR-
NAome could be a suitable approach for biomarker
detection in various diseases, including disorders of the
central nervous system8,65,66. Here we investigated the
hypothesis that miRNAs found in CSF exosomes may
inform about the pathogenesis of AD. We specifically
focused our analysis on CSF-derived exosomes, since at
least some of these exosomes likely stem from brain cells
and may thus reflect pathological changes occurring in
the brain. We detected miRNAs via smallRNA sequencing
of CSF-derived exosomes, which is in agreement with two
previous studies reporting the analysis of miRNAs
obtained from human CSF exosomes via PCR arrays27,24.
Another recent study reported successful smallRNA
sequencing from human CSF exosomes isolated from
three healthy donors67. In line with our observation, this
study also suggests a specific enrichment of miRNAs in
CSF exosomes when compared with the exosome-free
supernatant. The same study also reported a significant
overlap of miRNAs detected in CSF exosomes and the
human brain. This is in line with our comparative analysis
of human CSF exosomes and human postmortem brain
tissue, indicating that the CSF exosomal miRNAome—at
Fig. 3 A sncRNA signature to predict conversion of MCI patients. a Demographic information of the DCN longitudinal and multicenter cohort of
MCI. In total, baseline CSF exosomes from 17 participants diagnosed with MCI were analyzed. At the 10-year follow-up six individuals had converted
to dementia (3 male and 3 female). b ROC shows performance of our three piRNA signatures (identified in the signature cohort) on the DCN cohort
consisting of converting and stable MCI participants. c ROC with the mean AUC of 0.96 was obtained by using a combination of our piRNA signature
with pTau and Aβ42/40 ratio values. Error bars indicate SD
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least in part—reflects the CNS microRNAome. While the
precise role of CSF-derived exosomal miRNA remains to
be elucidated, there is recent evidence suggesting, for
example, a functional role of exosomal-released micro-
RNAs in brain aging68. Nevertheless, CSF-derived exo-
somes likely also stem from other sources than the brain,
and specific methods to enrich brain-derived exosomes
from CSF before sequencing will be necessary to provide
conclusive answers. We detected 3 miRNAs as part of a
six-sncRNA signature that helped to diagnose and predict
AD dementia, namely miR-34c, miR-30a, and miR-27a. It
is interesting that all three miRNAs have been linked to
AD via independent studies underscoring the importance
of our observation. To this end, miR-34c was found to be
upregulated in the hippocampus of mouse models for
amyloid deposition and age-associated memory decline11.
These data were confirmed in human postmortem brain
tissue from AD dementia patients11,21. In addition, inhi-
bition of miR-34c function ameliorated memory impair-
ment and gene expression in a mouse model for amyloid
deposition11. Interestingly, miR-34c was found to be ele-
vated in response to pathological stress69, which is in line
with data showing that stress-related diseases increase the
risk for developing dementia via aberrant gene activity70.
These data are also interesting since miR-30a expression
was associated with altered neuropeptide Y signaling—
that is intimately linked to stress-related neuropsychiatric
diseases56. Moreover, miR-30a was identified as a differ-
entially expressed miRNA in CSF from AD dementia
patients in an early study comparing microRNAs in 9
controls and 7 AD dementia patients (Braak and Braak
stage 5) via PCR array20. Another previous study reported
altered levels of miR-27a in CSF from AD dementia
patients and suggested the analysis of this miRNA as a
candidate biomarker57. It has to be noted that while the
increased expression of miR-34c and miR-30a is in line
with the previously reported expression data, miR-27a
was found to be decreased in CSF from AD dementia
patients57. This discrepancy to our findings may stem
from the fact that CSF exosomes were analyzed in our
study, and that, so far all available data represent cross-
sectional analysis. Thus, we speculate that dynamic
changes in miRNA expression may be observed when
patients are analyzed longitudinally. Another important
consideration is the fact that sample size of the employed
cohorts should be increased. It has to be mentioned that
Fig. 4 Performance of the CSF sncRNA signature in classifying patients on the basis of postmortem brain tissue. a Demographic information
for postmortem brain tissue samples included in the analysis (published dataset GSE48552). b The six sncRNA signatures defined via the analysis of
the signature cohort were tested on the data obtained from postmortem brain tissue (published brain cohort). ROC reveals a mean AUC of
0.89 suggesting that the sncRNA signature obtained from CSF helps to diagnose AD patients based on sncRNA expression in postmortem brain
tissue. c Upper panel shows the confirmed target genes of the three miRNAs that are part of our sncRNA signature. Lower panel shows the
significantly enriched signaling pathways based on the confirmed targets of the three miRNAs that are a part of the sncRNA signature. Error bars
indicate SD
Jain et al. Translational Psychiatry           (2019) 9:250 Page 9 of 12
some previous studies have analyzed microRNAs in CSF
of AD dementia patients by using different detection
methods such as PCR array20–24. The data among these
studies and our work are variable. One possible explana-
tion results from a recent work suggesting that con-
tamination of CSF with blood cells is a major confounding
factor when analyzing CSF miRNAs71. In such a scenario,
the analysis of cell-free CSF exosomes could be superior
to the analysis of total CSF and may also explain some of
the discrepancies among data. Moreover, different disease
stages of the analyzed patients could also explain differ-
ences in miRNA levels, and most studies—including ours
—are characterized by comparable small sample size, and
especially for the DCN cohort, we cannot exclude a
selection bias during the 10-year follow-up analysis.
In addition to miRNAs we detected a substantial
amount of piRNAs in CSF exosomes. To the best of our
knowledge, this is the first report that piRNAs are dif-
ferentially expressed in human CSF exosomes of AD
dementia patients. Our data are, however, in line with a
recent report suggesting that piRNAs might play an
important role in AD pathology, and more specifically
that Tau pathology disrupts piRNA function leading to
genome instability72. Moreover, loss of genome stability is
emerging as an important process in AD pathology73,72
and it is thus possible that the observed changes in CSF
piRNAs reflect the degree of neural genome instability. In
addition, piRNAs have been also associated with the
active regulation of gene expression in response to rele-
vant stimuli, and changes in piRNAs may thus also reflect
changes in cellular signaling. When compared with
microRNAs, the role of piRNAs is however less well
understood, and since piRNAs are also only poorly con-
served among species74, bioinformatic prediction of their
function is difficult at present. Future research needs to
address the role of the 3 piRNAs identified in our study in
human neuronal cells. Nevertheless, we speculate that the
analysis of miRNAs and piRNAs is especially suitable as a
candidate biomarker for complex diseases such as AD,
since changes in these sncRNA signatures may reflect
subtle changes in various signaling pathways critical for
cellular homeostasis65. In line with this idea, the pathway
analysis of the confirmed target genes from the three
miRNAs of our signature indicates neuroinflammatory
responses, altered IGF signaling, hypoxia, and mTOR
signaling, all processes that are intimately linked to AD
pathology59,61,62. As such, the analysis of sncRNA in CSF
exosomes likely informs about multiple pathological
processes that—when analyzed individually—would not
be able to classify patients.
An important issue is also the identification of pre-
dictive biomarkers that inform about the future conver-
sion to AD dementia. Recent advances suggest, for
example, that the analysis of neurofilament light-chain
protein in CSF is an early indicator of neuronal cell death
in individuals suffering from familial AD dementia75. It is
thus interesting that our reported piRNA signature was
able to predict conversion of MCI patients to dementia.
Nevertheless, these data have to be interpreted with care,
and larger cohorts need to be analyzed in future studies.
In conclusion, our data report a pi/miRNA signature
that helps to detect AD on the basis of CSF samples, and
may also help to predict conversion of MCI patients. Our
sncRNA signature reflects multiple homeostatic changes
in various cellular processes and thus further improves
the performance of established CSF biomarkers such as
the analysis of amyloid peptides and Tau protein. Since
smallRNAs are also very stable in cell-free environments,
are resistant to thaw–freeze cycles, and are less prone to
confounding factors related to the quantification method,
we suggest that the analysis of miRNAs/piRNAs and the
identified signature reported here in particular should be
further considered as a candidate biomarker for AD
stages.
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